Repligen Company, a life sciences firm centered on bioprocessing expertise management, at this time introduced it has entered right into a strategic partnership and unique license settlement with DRS Daylight Options to develop the usage of mid-infrared (mid-IR) expertise within the bioprocessing market.
By way of this settlement, Repligen will assume duty for the commercialization of Culpeo®, in addition to the event of future merchandise and applied sciences in partnership with DRS Daylight Options (“Daylight”). Each corporations will give attention to increasing the portfolio of Quantum Cascade Laser mid-IR (QCL-IR) based mostly options and integrating these options into Repligen Chromatography and Filtration techniques to develop the businesses’ presence within the fast-growing Course of Analytics Expertise (PAT) section of the bioprocessing market.
Daylight’s patented QCL-IR expertise measures increased order protein and nucleic acid construction, facilitating the measurement of protein aggregation, focus and nucleic acid content material and different important attributes in organic manufacturing processes. Correct readouts can be found in seconds, enabling real-time course of monitoring in upstream and downstream manufacturing.
San Diego-based Daylight specializes within the growth and manufacturing of progressive options based mostly on its QCL expertise platform, which operates all through the mid-IR spectral vary. Daylight, recognized for best-in-class merchandise supporting business, analysis, and aerospace and protection markets, entered the bioprocessing market in 2018 with its ground-breaking Culpeo® instrument.
We’re delighted to have signed this settlement with DRS Daylight Options, which enhances our current analytics portfolio from C Applied sciences, a pioneer in real-time, in-line course of monitoring options. We imagine that the Daylight portfolio will serve to speed up and develop adoption of in-line course of monitoring within the bioprocessing business. We sit up for working with Tim Day and the crew at Daylight.”
Tony J. Hunt, CEO, Repligen Company
Dr. Timothy Day, Senior Vice President and Normal Supervisor, DRS Daylight Options, stated, “We’re very excited to accomplice with Repligen to make QCL-IR based mostly options a game-changing expertise in PAT. We imagine Repligen is the perfect accomplice to perform this, given their success with C Applied sciences and their observe report of innovation in bioprocessing. We sit up for working along with Tony Hunt and the Repligen crew to supply bioprocessing prospects this ground-breaking expertise to measure important course of parameters in biologics manufacturing. With real-time and excessive reliability outcomes, Culpeo® will in the end enhance manufacturing yields, cut back prices and guarantee product high quality.”